#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	1236	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2296	108.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1603	1603	C	155	C	101	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	1236	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2296	108.1	0	HET	.	.	.	C207T	.	207	207	C	626	626	C	121	C,T	64,18	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	1236	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2296	108.1	0	HET	.	.	.	C451T	.	451	451	C	870	870	C	101	C,T	37,31	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	1236	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2296	108.1	0	HET	.	.	.	G421A	.	421	421	G	840	840	G	108	G,A	55,16	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	2316	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3759	121.2	0	.	n	.	0	T695C	SNP	695	695	T	1108	1108	C	194	C	122	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	2316	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3759	121.2	0	.	n	.	0	C1811T	SNP	1811	1811	C	2224	2224	T	111	T,C	67,15	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	2316	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3759	121.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2384	2384	C	116	C	81	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	2316	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3759	121.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3010	3010	T	121	T,C	69,15	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	2316	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3759	121.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2458	2458	A	131	A	95	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	2316	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3759	121.2	0	HET	.	.	.	C993T	.	993	993	C	1406	1406	C	129	C,T	60,24	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	90	folP	855	855	100.0	folP.l15.c4.ctg.1	1297	12.9	1	SNP	p	R229S	1	.	.	685	687	AGC	821	823	AGC	22;22;22	A;G;C	16;16;15	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	517	210	gyrA	2751	2271	99.78	gyrA.l15.c4.ctg.1	2342	13.7	0	.	p	.	0	T583P	NONSYN	1747	1749	ACC	1818	1820	CCC	9;9;9	C,A;C;C	0,4;7;7	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	517	210	gyrA	2751	2271	99.78	gyrA.l15.c4.ctg.1	2342	13.7	1	SNP	p	S91F	1	.	.	271	273	TTC	342	344	TTC	14;14;14	T;T;C	9;8;8	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	517	210	gyrA	2751	2271	99.78	gyrA.l15.c4.ctg.1	2342	13.7	1	SNP	p	D95G	1	.	.	283	285	GGC	354	356	GGC	14;14;14	G;G;C	9;9;8	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	517	210	gyrA	2751	2271	99.78	gyrA.l15.c4.ctg.1	2342	13.7	1	SNP	p	G95N	0	.	.	283	285	GGC	354	356	GGC	14;14;14	G;G;C	9;9;8	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	517	210	gyrA	2751	596	97.33	gyrA.l15.c4.ctg.2	1127	6.8	0	.	p	.	0	W721fs	FSHIFT	2161	2161	T	61	61	T	1	T	1	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	16	70	mtrR	633	486	100.0	mtrR.l15.c4.ctg.1	654	13.8	1	SNP	p	G45D	0	.	.	133	135	GGC	301	303	GGC	16;16;16	G;G;C	10;10;10	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	52	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	459	15.7	0	.	n	.	0	A197.	DEL	197	197	A	319	319	A	20	A	14	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	178	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2797	11.9	1	SNP	p	D86N	0	.	.	256	258	GAC	455	457	GAC	9;11;11	G;A;C	8;9;9	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	178	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2797	11.9	1	SNP	p	R87W	0	.	.	259	261	CGT	458	460	CGT	11;11;11	C;G;T	9;9;9	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	178	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2797	11.9	1	SNP	p	R87I	0	.	.	259	261	CGT	458	460	CGT	11;11;11	C;G;T	9;9;9	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	178	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2797	11.9	1	SNP	p	S87R	1	.	.	259	261	CGT	458	460	CGT	11;11;11	C;G;T	9;9;9	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	178	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2797	11.9	1	SNP	p	S88P	0	.	.	262	264	TCC	461	463	TCC	11;11;11	T;C;C	9;9;9	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	517	176	parE	1986	1805	100.0	parE.l15.c4.ctg.1	1901	14.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1047	1049	GGC	15;15;16	G;G;C	9;10;10	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	517	176	parE	1986	364	99.45	parE.l15.c4.ctg.2	588	11.2	0	.	p	.	0	T94P	NONSYN	280	282	ACC	504	506	CCC	4;4;4	C;C;C	0;4;4	.	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	A311V	0	.	.	931	933	GCC	1229	1231	GCC	24;26;26	G;C;C	17;18;19	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	I312M	1	.	.	934	936	ATG	1232	1234	ATG	26;26;26	A;T;G	20;19;17	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	T316P	0	.	.	946	948	ACC	1244	1246	ACC	27;27;27	A;C;C	18;19;20	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	V316T	1	.	.	946	948	ACC	1244	1246	ACC	27;27;27	A;C;C	18;19;20	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1745	1747	ACC	24;24;24	A;C;C	13;14;16	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1799	1801	GCG	30;30;30	G;C,G;G	17;17,1;17	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1799	1801	GCG	30;30;30	G;C,G;G	17;17,1;17	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1922	1924	GGT	19;19;19	G;G;T	13;13;13	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1931	1933	AGC	18;16;16	A;G;C	12;12;11	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	222	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2204	19.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1949	1951	CCG	10;10;10	C;C;G	7;7;7	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	408	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	2880	26.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1544	1546	CCG	18;18;18	C;C;G,A	11;11;11,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	160	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1543	19.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	447	447	C	8	C	6	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	138	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1350	18.4	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	230	232	CAG	15;15;15	C;A;G	10;10;10	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	138	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1350	18.4	1	SNP	p	G120K	1	.	.	358	360	AAG	470	472	AAG	14;14;14	A;A;G	10;12;11	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	138	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1350	18.4	1	SNP	p	A121N	1	.	.	361	363	AAC	473	475	AAC	14;14;14	A;A;C	12;10;12	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	138	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1350	18.4	1	SNP	p	N121D	0	.	.	361	363	AAC	473	475	AAC	14;14;14	A;A;C	12;10;12	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	584	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4626	25.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	46	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1051	9.4	1	SNP	p	V57M	1	.	.	169	171	ATG	448	450	ATG	19;19;19	A;T;G	13;12;13	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
